IP Library Granted Patent US 9,902,991
Granted Patent B2
US 9,902,991 · App. 14/644,455 · Granted Feb 27, 2018

Methods for depleting RNA from nucleic acid samples

Inventors: Dominick Sinicropi (Woodside, CA); John Morlan (Foster City, CA)
Assignee: GENOMIC HEALTH, INC.
C12Q1/6806C12N15/1003C12Q1/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,991
App. No.
14/644,455
Granted
Feb 27, 2018
Kind
B2
Abstract

The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.

Claims (32)

1. A composition comprising:

(a) a mixture comprising a plurality of RNA molecules, comprising target and non-target RNA molecules;

(b) a multiplicity of DNA probes comprising a plurality of synthetic DNA oligonucleotides capable of selectively hybridizing to the target RNA molecules in the mixture to produce DNA-RNA hybrids, wherein the plurality of synthetic DNA oligonucleotides is capable of selectively hybridizing along the entire full length sequence of the target RNA molecules; and

(c) an RNase for cleaving the DNA-RNA hybrids, wherein the RNase is capable of degrading the target RNA molecules in the DNA-RNA hybrids,

wherein, in the composition, the plurality of synthetic DNA oligonucleotides of (b) is selectively hybridized along the entire full length sequence of the target RNA molecules of (a), and wherein the multiplicity of DNA probes comprises at least two probes complementary to RNA sequences that overlap one another.

2. The composition of claim 1 , wherein the target RNA molecules have a poly(A) tail.

3. The composition of claim 1 , wherein the target RNA molecules lack a poly(A) tail.

4. The composition of claim 3 , wherein the target RNA molecules lacking a poly(A) tail comprise ribosomal RNA (rRNA) or transfer RNA (tRNA).

5. The composition of claim 4 , wherein the target RNA molecules lacking a poly(A) tail comprise rRNA, and wherein the rRNA is eukaryotic rRNA.

6. The composition of claim 5 , wherein the eukaryotic rRNA comprises one or more of the following eukaryotic rRNAs: cytoplasmic 5S rRNA, cytoplasmic 5.8S rRNA, cytoplasmic 18S rRNA, cytoplasmic 28S rRNA, mitochondrial 12S rRNA or mitochondrial 18S rRNA.

7. The composition of claim 4 , wherein the target RNA molecules lacking a poly(A) tail comprise rRNA, and wherein the rRNA is prokaryotic rRNA.

8. The composition of claim 7 , wherein the prokaryotic rRNA comprises one or more of the following prokaryotic rRNAs: 5S rRNA, 16S rRNA, and 23S rRNA.

9. The composition of claim 1 , wherein the multiplicity of DNA probes comprises DNA probes that are not labeled with a reporter group moiety, an enzyme, or a ligand used for detection or confirmation of hybridization of the multiplicity of DNA probes to the target RNA sequence.

10. The composition of claim 1 , wherein the RNase is RNase H.

11. The composition of claim 1 , wherein the multiplicity of DNA probes are 10 to 100 nucleotides in length.

12. The composition of claim 11 , wherein the multiplicity of DNA probes are 14 to 85 nucleotides in length.

13. A composition comprising:

(a) a mixture comprising a plurality of RNA molecules, comprising target and non-target RNA molecules;

(b) a multiplicity of DNA probes comprising a plurality of synthetic DNA oligonucleotides capable of selectively hybridizing to the target RNA molecules in the mixture to produce DNA-RNA hybrids, wherein the plurality of synthetic DNA oligonucleotides is capable of selectively hybridizing along the entire full length sequence of the target RNA molecules; and

(c) an RNase for cleaving the DNA-RNA hybrids, wherein the RNase is capable of degrading the target RNA molecules in the DNA-RNA hybrids,

wherein, in the composition, the plurality of synthetic DNA oligonucleotides of (b) is selectively hybridized along the entire full length sequence of the target RNA molecules of (a), and wherein the multiplicity of DNA probes comprises at least two probes complementary to RNA sequences that overlap one another, and wherein the plurality of RNA molecules is obtained from a fixed paraffin-embedded tissue (FPET) sample.

14. The composition of claim 13 , wherein the target RNA molecules have a poly(A) tail.

15. The composition of claim 13 , wherein the target RNA molecules lack a poly(A) tail.

16. The composition of claim 15 , wherein the target RNA molecules lacking a poly(A) tail comprise ribosomal RNA (rRNA) or transfer RNA (tRNA).

17. The composition of claim 16 , wherein the target RNA molecules lacking a poly(A) tail comprise rRNA, and wherein the rRNA is eukaryotic rRNA.

18. The composition of claim 17 , wherein the eukaryotic rRNA comprises one or more of the following eukaryotic rRNAs: cytoplasmic 5S rRNA, cytoplasmic 5.8S rRNA, cytoplasmic 18S rRNA, cytoplasmic 28S rRNA, mitochondrial 12S rRNA or mitochondrial 18S rRNA.

19. The composition of claim 16 , wherein the target RNA molecules lacking a poly(A) tail comprise rRNA, and wherein the rRNA is prokaryotic rRNA.

20. The composition of claim 19 , wherein the prokaryotic rRNA comprises one or more of the following prokaryotic rRNAs: 5S rRNA, 16S rRNA, and 23S rRNA.

21. The composition of claim 13 , wherein the multiplicity of DNA probes comprises DNA probes that are not labeled with a reporter group moiety, an enzyme, or a ligand used for detection or confirmation of hybridization of the multiplicity of DNA probes to the target RNA sequence.

22. The composition of claim 13 , wherein the RNase is RNase H.

23. The composition of claim 13 , wherein the multiplicity of DNA probes are 10 to 100 nucleotides in length.

24. The composition of claim 13 , wherein the multiplicity of DNA probes are 14 to 85 nucleotides in length.

Assignments (2)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0380) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: GENOMIC HEALTH, INC.
Reel/Frame 075294/0821 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: GENOMIC HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0380 →
Continuity (3)
Division 12940981 · Nov 5, 2010
Provisional Application 61259934 · Nov 10, 2009
Related Publication 20150299771A1 · Oct 22, 2015